Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "BioSpace" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about BioSpace for you to read. Along with our medical data and news we also list BioSpace Clinical Trials, which are updated daily. BioPortfolio also has a large database of BioSpace Companies for you to search.
The U.S. Food and Drug Administration (FDA) granted San Diego-based Evofem Biosciences Fast Track designation for Amphora vaginal gel to prevent urogenital chlamydia infection in women.
Aimmune Therapeutics announced late-stage trial results that showed its peanut allergy therapy was effective in more than 67 percent of juvenile patients.
Dynavax announced it has secured a $175 million non-dilutive term loan agreement to commercialize Heplisav-B.
AbbVie and Voyager Therapeutics inked a collaboration deal to develop treatments for Alzheimer’s disease and other neurodegenerative diseases.
Life sciences giant Johnson & Johnson may be shopping around its sterilization products division.
Federal court judge orders Merck to repay $2.5 Billion to Gilead in overturned patent decision.
The U.S. Food and Drug Administration (FDA) approved AstraZeneca’s Imfinzi to treat patients with unresectable Stage III non-small cell lung cancer (NSCLC).
Nevada-based PDL BioPharma, Inc. said it will no longer pursue a proposed acquisition of Neos Therapeutics.
Some analysts are scratching their head over Warren Buffet's investment in Teva Pharma.
RELIEF™ trial demonstrated statistically significant reductions in oral ulcers with apremilast 30 mg versus placebo through week 12.
AbbVie today presented new positive results from a Phase 2b dose-ranging study evaluating upadacitinib, an investigational, once-daily oral JAK1-selective inhibitor, in adult patients with moderate to severe atopic dermatitis.
AbbVie presented today new positive results from the pivotal Phase 3 ultIMMa-1 and ultIMMa-2 replicate clinical trials that evaluated the safety and efficacy of risankizumab (150 mg) compared to placebo or ustekinumab (45 or 90 mg, based on patient weight).
Analysts with The Motley Fool looked at three biotech stocks that even biotech-leery investors might consider.
Despite the recent dismal news regarding Alzheimer’s drug development, the U.S. Food and Drug Administration (FDA) recently proposed new guidelines for developing drugs for the disease.
Three biotech stocks gained over 25 percent last week.
Novartis may soon be looking to sell off its generics subsidiary Sandoz.
Eli Lilly and its Korean collaborative partner Hanmi stopped a Phase II trial on an experimental rheumatoid arthritis treatment following less-than-stellar interim results.
IMFINZI is the only immunotherapy approved for patients with unresectable Stage III non-small cell lung cancer.
The new campus will consolidate some 400 employees in one place and give more space to the startup companies it helps.
Government officials say they are now certain they know who launched the NotPetya cyberwar that slammed operations at Merck last year.
Novavax is hot right now -- but just how much hotter could this biotech stock get?
Makena was approved by the FDA in February 2011 and remains the first and only FDA-approved treatment option currently available for pregnant women who have had a prior spontaneous preterm birth.
The CRL indicates that the FDA cannot approve the NDA for Vitaros in its present form.
The 915,000-square-foot facility on Research Parkway was purchased this week by Calare Properties.
Roche will plunk down $1.9M to acquire Flatiron Health, which has previously been backed by GV, as well as Roche.